# A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

> **NCT06970119** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yunhe Pharmaceutical (Tianjin) Co., Ltd** · enrollment: 55 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** INR102 injection

## Key facts

- **NCT ID:** NCT06970119
- **Lead sponsor:** Yunhe Pharmaceutical (Tianjin) Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-14
- **Primary completion:** 2029-06-20
- **Final completion:** 2029-10-22
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06970119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06970119, "A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06970119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*